The expression changes we found for CYP2C19 and other pharmacogenes would likely have been more precisely characterized by including known loss-of-function genotypes in the analysis, but since genotypes are unlikely to cluster in severe NAFLD patients, this is not a major limitation. The gene discussed is CYP2C19; the disease is metabolic dysfunction-associated steatotic liver disease.